These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

674 related items for PubMed ID: 26155832

  • 1. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, Kaur B, Caligiuri MA, Yu J.
    Sci Rep; 2015 Jul 09; 5():11483. PubMed ID: 26155832
    [Abstract] [Full Text] [Related]

  • 2. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A.
    J Immunother; 2015 Jun 09; 38(5):197-210. PubMed ID: 25962108
    [Abstract] [Full Text] [Related]

  • 3. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
    Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, Chen L, Wang Y, Wang H, Yi L, Elder JB, Wang QE, He X, Kaur B, Chiocca EA, Yu J.
    Oncotarget; 2016 May 10; 7(19):27764-77. PubMed ID: 27050072
    [Abstract] [Full Text] [Related]

  • 4. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z.
    Cancer Immunol Res; 2018 Nov 10; 6(11):1314-1326. PubMed ID: 30201736
    [Abstract] [Full Text] [Related]

  • 5. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
    Ma R, Lu T, Li Z, Teng KY, Mansour AG, Yu M, Tian L, Xu B, Ma S, Zhang J, Barr T, Peng Y, Caligiuri MA, Yu J.
    Cancer Res; 2021 Jul 01; 81(13):3635-3648. PubMed ID: 34006525
    [Abstract] [Full Text] [Related]

  • 6. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R, Wang S, Hacker U, Büning H, Morgan M, Dörk T, Hillemanns P, Schambach A.
    Hum Gene Ther; 2017 Oct 01; 28(10):886-896. PubMed ID: 28836469
    [Abstract] [Full Text] [Related]

  • 7. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
    Liu Y, Zhou Y, Huang KH, Fang X, Li Y, Wang F, An L, Chen Q, Zhang Y, Shi A, Yu S, Zhang J.
    Cell Prolif; 2020 Aug 01; 53(8):e12858. PubMed ID: 32592435
    [Abstract] [Full Text] [Related]

  • 8. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S, Burger MC, Zhang C, Oelsner S, Mildenberger I, Wagner M, Steinbach JP, Wels WS.
    Oncoimmunology; 2016 Apr 01; 5(4):e1119354. PubMed ID: 27141401
    [Abstract] [Full Text] [Related]

  • 9. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A, Sanchez C, Bullain S, Waterman P, Weissleder R, Carter BS.
    PLoS One; 2018 Apr 01; 13(7):e0199414. PubMed ID: 29975720
    [Abstract] [Full Text] [Related]

  • 10. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
    Murakami T, Nakazawa T, Natsume A, Nishimura F, Nakamura M, Matsuda R, Omoto K, Tanaka Y, Shida Y, Park YS, Motoyama Y, Nakagawa I, Yamada S, Tamura K, Takeshima Y, Takamura Y, Wakabayashi T, Nakase H.
    Anticancer Res; 2018 Sep 01; 38(9):5049-5056. PubMed ID: 30194149
    [Abstract] [Full Text] [Related]

  • 11. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K, Cartellieri M, Michen S, Wiedemuth R, Müller N, Lindemann D, Bachmann M, Füssel M, Schackert G, Temme A.
    J Immunol; 2015 Apr 01; 194(7):3201-12. PubMed ID: 25740942
    [Abstract] [Full Text] [Related]

  • 12. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.
    J Hematol Oncol; 2013 May 09; 6():33. PubMed ID: 23656794
    [Abstract] [Full Text] [Related]

  • 13. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
    Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J.
    Leukemia; 2014 Apr 09; 28(4):917-27. PubMed ID: 24067492
    [Abstract] [Full Text] [Related]

  • 14. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
    Nakazawa T, Murakami T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, Park YS, Motoyama Y, Tsujimura T, Wakabayashi T, Nakase H.
    Anticancer Res; 2020 Jun 09; 40(6):3231-3237. PubMed ID: 32487617
    [Abstract] [Full Text] [Related]

  • 15. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H, You Y, Shen Z, Shi L.
    Pathol Oncol Res; 2020 Oct 09; 26(4):2135-2141. PubMed ID: 31989402
    [Abstract] [Full Text] [Related]

  • 16. Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.
    Zhang Q, Tian K, Xu J, Zhang H, Li L, Fu Q, Chai D, Li H, Zheng J.
    J Immunol Res; 2017 Oct 09; 2017():6915912. PubMed ID: 29423418
    [Abstract] [Full Text] [Related]

  • 17. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC, Zhang C, Harter PN, Romanski A, Strassheimer F, Senft C, Tonn T, Steinbach JP, Wels WS.
    Front Immunol; 2019 Oct 09; 10():2683. PubMed ID: 31798595
    [Abstract] [Full Text] [Related]

  • 18. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.
    Cytotherapy; 2017 Feb 09; 19(2):235-249. PubMed ID: 27887866
    [Abstract] [Full Text] [Related]

  • 19. Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells.
    Wang J, Lupo KB, Chambers AM, Matosevic S.
    J Immunother Cancer; 2018 Dec 04; 6(1):136. PubMed ID: 30514403
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.
    Ohta K, Sakoda Y, Adachi K, Shinozaki T, Nakajima M, Yasuda H, Nagano H, Tamada K.
    Cancer Res Commun; 2024 Sep 01; 4(9):2514-2524. PubMed ID: 39240078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.